Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention.

dc.contributor.author

Zhao, Xueyan

dc.contributor.author

Li, Jianxin

dc.contributor.author

Tang, Xiaofang

dc.contributor.author

Xian, Ying

dc.contributor.author

Jiang, Lin

dc.contributor.author

Chen, Jue

dc.contributor.author

Gao, Lijian

dc.contributor.author

Gao, Zhan

dc.contributor.author

Qiao, Shubin

dc.contributor.author

Yang, Yuejin

dc.contributor.author

Gao, Runlin

dc.contributor.author

Xu, Bo

dc.contributor.author

Yuan, Jinqing

dc.date.accessioned

2020-10-21T19:08:54Z

dc.date.available

2020-10-21T19:08:54Z

dc.date.issued

2019-01

dc.date.updated

2020-10-21T19:08:53Z

dc.description.abstract

The Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) thrombotic risk score is a novel score for predicting the risk of coronary thrombotic events after percutaneous coronary intervention (PCI). We assessed the prognostic value of this score for mortality in patients with PCI. In this prospective, observational study, we enrolled 10 724 consecutive patients underwent PCI. The primary end point was all-cause death and the secondary end point was major adverse cardiovascular and cerebrovascular events (MACCE) as a composite of all-cause death, myocardial infarction, revascularization, stent thrombosis, or stroke. Among 9782 patients without in-hospital events, a total of 97 deaths and 1002 MACCE occurred during the 2-year follow-up. The mortality risk of patients in the high-risk group was 2.31 times higher than that in the low-risk group (hazard ratio, 2.31; P = .001). This risk score showed prognostic value in evaluating mortality (area under the receiver operating characteristic curve [AUROC], 0.607; 95% confidence interval [CI], 0.551-0.663) and MACCE (AUROC, 0.544; 95% CI, 0.526-0.563; both P < .001). The prognostic value of mortality was higher than that of MACCE (Z = 2.09, P = .04). The PARIS thrombotic risk score shows modest prognostic value for mortality and MACCE, and the prognostic value of mortality is better than that of MACCE.

dc.identifier.issn

1076-0296

dc.identifier.issn

1938-2723

dc.identifier.uri

https://hdl.handle.net/10161/21622

dc.language

eng

dc.publisher

SAGE Publications

dc.relation.ispartof

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

dc.relation.isversionof

10.1177/1076029619853638

dc.subject

Humans

dc.subject

Cerebrovascular Disorders

dc.subject

Thrombosis

dc.subject

Prognosis

dc.subject

Mortality

dc.subject

Risk Assessment

dc.subject

Prospective Studies

dc.subject

ROC Curve

dc.subject

Aged

dc.subject

Middle Aged

dc.subject

Female

dc.subject

Male

dc.subject

Percutaneous Coronary Intervention

dc.title

Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention.

dc.type

Journal article

duke.contributor.orcid

Xian, Ying|0000-0002-1237-1162

pubs.begin-page

1076029619853638

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Neurology, Neurocritical Care

pubs.organisational-group

Medicine, Clinical Pharmacology

pubs.organisational-group

Duke

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Neurology

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.publication-status

Published

pubs.volume

25

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention.pdf
Size:
262.77 KB
Format:
Adobe Portable Document Format
Description:
Published version